Compare DexCom, Inc. (DXCM) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs TKO Group Holdings Inc — how do they compare? DexCom, Inc. trades at $84.88 (market cap $31.86B), while TKO Group Holdings Inc trades at $180.97 (market cap $13.28B). The key difference: DexCom, Inc. is far larger — about 2.4× TKO Group Holdings Inc's market cap, and TKO Group Holdings Inc pays a 1.74% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and TKO Group Holdings Inc for 30 Days on average.
| DXCM | TKO | |
|---|---|---|
Market Cap | $31.86B | $13.28B |
Volume | 3,607,070 | 857,653 |
Sector | Health | Media |
52-Week High | $92.34 | $224.96 |
52-Week Low | $54.84 | $175.58 |
Typical Hold Time | 62 Days | 30 Days |
Enterprise Value | $31.32B | $17.64B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
TKO trades at $178.64, up 1.24% on the day but near recent lows, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year guidance. Revenue growth is solid, with 2026 projected at $5.3B, though net margins remain thin at 4.33%. A quarterly dividend of $0.79 was declared for payment in September 2026.
The stock presents a contrast between strong analyst bullishness (89% buy rating, $227 consensus target) and current technical weakness. Upside hinges on execution of media rights monetization and live event growth, while risks include competitive pressures and margin sustainability. The valuation at a P/E of 63.73 demands high future earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
